HDAC1型
药效团
细胞周期蛋白依赖激酶7
癌症研究
细胞凋亡
组蛋白脱乙酰基酶
结直肠癌
组蛋白脱乙酰酶抑制剂
癌症
化学
癌细胞
激酶
乙酰化
生物
组蛋白
细胞周期
生物化学
细胞周期蛋白依赖激酶2
遗传学
基因
作者
Yao Chen,Shuangqian Zhang,Zhijia Li,Bin Yin,Yi Liu,Lan Zhang
标识
DOI:10.1002/cmdc.202300281
摘要
Abstract Aberrant expression or dysfunction of cyclin‐dependent kinase 7(CDK7) and histone deacetylase 1 (HDAC1) are associated with the occurrence and progression of various cancers. In this study, we developed a series of dual‐target inhibitors by designing and synthesizing compounds that incorporate the pharmacophores of THZ2 and SAHA. The most potent dual‐target inhibitor displayed robust inhibitory activity against several types of cancer cells and demonstrated promising inhibitory effects on both CDK7 and HDAC1. After further mechanistic studies, it was discovered that this inhibitor effectively arrested HCT‐116 cells at the G2 phase and induced apoptosis. Additionally, it also significantly hindered the migration of HCT‐116 cells and exhibited notable anti‐tumor effects. These findings offer strong support for the development of dual‐target inhibitors of CDK7 and HDAC1 and provide a promising avenue for future cancer therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI